{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:34:21Z","timestamp":1785882861226,"version":"3.56.0"},"reference-count":31,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,7,15]]},"DOI":"10.2169\/internalmedicine.2475-23","type":"journal-article","created":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T22:11:36Z","timestamp":1702246296000},"page":"2089-2096","source":"Crossref","is-referenced-by-count":5,"title":["Development of Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome with Pembrolizumab for Lung Squamous Cell Carcinoma"],"prefix":"10.2169","volume":"63","author":[{"given":"Misaki","family":"Yoshida","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Kanazawa University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kanazawa University Hospital, Japan"},{"name":"Medical Education Research Center, Graduate School of Medical Sciences, Kanazawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kanazawa University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanazawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Murase","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanazawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideharu","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanazawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Mizushima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kanazawa University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kanazawa University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 33: 1974-1982, 2015.","DOI":"10.1200\/JCO.2014.59.4358"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378: 158-168, 2018.","DOI":"10.1056\/NEJMra1703481"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Angelopoulou F, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D. Immune checkpoint inhibitor-induced musculoskeletal manifestations. Rheumatol Int 41: 33-42, 2021.","DOI":"10.1007\/s00296-020-04665-7"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wada N, Uchi H, Furue M. Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma. J Dermatol 44: e196-e197, 2017.","DOI":"10.1111\/1346-8138.13840"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ngo L, Miller E, Valen P, Gertner E. Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report. J Med Case Rep 12: 48, 2018.","DOI":"10.1186\/s13256-018-1579-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kim ST, Murphy WA Jr, Aparicio A, Subudhi SK. RS3PE following treatment with combination of hormonal therapies plus ipilimumab in a patient with metastatic prostate cancer. J Immunother Precis Oncol 3: 128-132, 2020.","DOI":"10.36401\/JIPO-20-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Lakhmalla M, Dahiya DS, Kichloo A, Fatima T, Edigin E, Wani F. Remitting seronegative symmetrical synovitis with pitting edema: a review. J Investig Med 69: 86-90, 2021.","DOI":"10.1136\/jim-2020-001613"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Hansmaennel A, Verhoeven F, Chouk M, Prati C, Aubin F, Wendling D. RS3PE syndrome induced by Pembrolizumab. Joint Bone Spine 88: 105216, 2021.","DOI":"10.1016\/j.jbspin.2021.105216"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yoshimura A, Yamanaka K, Tadokoro R, et al. Remitting seronegative symmetrical synovitis with pitting edema syndrome induced by pembrolizumab in patient with urothelial carcinoma. IJU Case Rep 5: 219-222, 2022.","DOI":"10.1002\/iju5.12426"},{"key":"10","doi-asserted-by":"crossref","first-page":"e000428","DOI":"10.1136\/rmdopen-2016-000428","volume":"3","author":"MA D'Agostino","year":"2017","unstructured":"10. D&apos;Agostino MA, Terslev L, Aegerter P, et al. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce - part 1: definition and development of a standardised, consensus-based scoring system. RMD Open 3: e000428, 2017.","journal-title":"RMD Open","ISSN":"https:\/\/id.crossref.org\/issn\/2056-5933","issn-type":"print"},{"key":"11","unstructured":"11. Brahmer JR, Lacchetti C, Schneider BJ, et al.; the National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36: 1714-1768, 2018."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc 85: 838-854, 2010.","DOI":"10.4065\/mcp.2010.0099"},{"key":"13","unstructured":"13. Oliv\u00e9 A, del Blanco J, Pons M, Vaquero M, Tana X. The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catal\u00e1n Group for the Study of RS3PE. J Rheumatol 24: 333-336, 1997."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Borges T, Silva S. RS3PE syndrome: autoinflammatory features of a rare disorder. Mod Rheumatol 33: 640-646, 2023.","DOI":"10.1093\/mr\/roac071"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum 40: 89-94, 2010.","DOI":"10.1016\/j.semarthrit.2008.11.006"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Li H, Altman RD, Yao Q. RS3PE: clinical and research development. Curr Rheumatol Rep 17: 49, 2015.","DOI":"10.1007\/s11926-015-0525-0"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Varshney AN, Singh NK. Syndrome of remitting seronegative symmetrical synovitis with pitting edema: a case series. J Postgrad Med 61: 38-41, 2015.","DOI":"10.4103\/0022-3859.147038"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Horai Y, Shimizu T, Okada A, et al. Dipeptidyl peptidase-4 inhibitor use is associated with a lower erythrocyte sedimentation rate in patients with remitting seronegative symmetrical synovitis with pitting oedema and pre-existing diabetes mellitus. Mod Rheumatol 32: 830-833, 2022.","DOI":"10.1093\/mr\/roab036"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gauci ML, Baroudjian B, Laly P, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab. Semin Arthritis Rheum 47: 281-287, 2017.","DOI":"10.1016\/j.semarthrit.2017.03.003"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Filetti M, Anselmi E, Macrini S, et al. Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report. Semin Arthritis Rheum 48: e17-e20, 2018.","DOI":"10.1016\/j.semarthrit.2017.12.013"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Amini-Adle M, Piperno M, Tordo J, et al. Remitting seronegative symmetric synovitis with pitting edema associated with partial melanoma response under anti-CTLA-4 and anti-programmed death 1 combination treatment. Arthritis Rheumatol 70: 1358, 2018.","DOI":"10.1002\/art.40506"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Redman JM, Rhea LP, Cordes L, et al. A case of anti-PD-L1-associated remitting seronegative symmetric synovitis with pitting edema. Clin Genitourin Cancer 17: e549-e552, 2019.","DOI":"10.1016\/j.clgc.2019.02.005"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Chennamadhavuni A, Abushahin L, Jin N, Presley JP, Manne A. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol 13: 779691, 2022.","DOI":"10.3389\/fimmu.2022.779691"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis 64: 1653-1655, 2005.","DOI":"10.1136\/ard.2004.032995"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kenzaka T. The relationship between remitting seronegative symmetrical synovitis with pitting edema and vascular endothelial growth factor and matrix metalloproteinase 3. Intern Med 59: 1021-1022, 2020.","DOI":"10.2169\/internalmedicine.4239-19"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kawashiri SY, Nakano M, Kawakami A, Eguchi K. Monitoring of therapeutic efficacy in a patient with RS<sub>3<\/sub>PE syndrome by serologic variables and radiographic methods. Rheumatol Int 30: 1677-1680, 2010.","DOI":"10.1007\/s00296-009-1142-x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Origuchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol 22: 584-588, 2012.","DOI":"10.3109\/s10165-011-0556-y"},{"key":"28","unstructured":"28. Karmacharya P, Donato AA, Aryal MR, et al. RS3PE revisited: a systematic review and meta-analysis of 331 cases. Clin Exp Rheumatol 34: 404-415, 2016."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 36: 2872-2878, 2018.","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 7: 306, 2019.","DOI":"10.1186\/s40425-019-0805-8"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Skribek M, Rounis K, Afshar S, et al. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Eur J Cancer 145: 245-254, 2021.","DOI":"10.1016\/j.ejca.2020.12.012"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/14\/63_2475-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T03:29:25Z","timestamp":1721446165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/14\/63_2475-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":31,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2475-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"article-number":"2475-23"}}